Market closed

Replimune/$REPL

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Replimune

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Ticker

$REPL
Trading on

Industry

Biotechnology

Employees

331

Replimune Metrics

BasicAdvanced
$835M
Market cap
-
P/E ratio
-$3.27
EPS
1.25
Beta
-
Dividend rate
$835M
1.25
$12.38
$4.92
583K
13.462
13.286
16.895
17.81
-33.69%
-25.74%
-46.79%
1.96
1.96
-4.258
10.31%
21.02%

What the Analysts think about Replimune

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Replimune stock.

Replimune Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Replimune Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $REPL

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Replimune stock?

Replimune (REPL) has a market cap of $835M as of November 08, 2024.

What is the P/E ratio for Replimune stock?

The price to earnings (P/E) ratio for Replimune (REPL) stock is 0 as of November 08, 2024.

Does Replimune stock pay dividends?

No, Replimune (REPL) stock does not pay dividends to its shareholders as of November 08, 2024.

When is the next Replimune dividend payment date?

Replimune (REPL) stock does not pay dividends to its shareholders.

What is the beta indicator for Replimune?

Replimune (REPL) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.